广济药业公告称，于2026年1月9日召开董事会会议，同意对全资子公司生物研究院减少注册资本2200万 元。减资前，生物研究院注册资本为5000万元，减资后将减至2800万元，公司仍持股100%，不影响合 并报表范围。生物研究院2025年1 - 9月营收235.85万元、净利润 - 131.02万元，2024年营收59.91万元、 净利润 - 576.12万元。本次减资是基于战略规划，利于优化资产结构，提升管理效率，不会对当期损益 造成重大影响。 ...

Group 1 - The chemical pharmaceutical sector increased by 0.24% on January 8, with Bibete leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - Notable gainers in the chemical pharmaceutical sector included Bibete, which rose by 20.00% to a closing price of 49.68, and Qijingt, which increased by 10.00% to 28.27 [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 191 million yuan from institutional investors, while retail investors saw a net inflow of approximately 84.42 million yuan [2] - The trading volume for Bibete was 140,500 shares, with a transaction value of 682 million yuan, indicating strong market interest [1] - The sector's overall trading activity showed a mix of inflows and outflows, with specific stocks like Hainan Haiyao and Xinyu Pharmaceutical seeing significant institutional interest [3]

（文章来源：证券日报） 证券日报网讯 1月6日，广济药业在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东 总户数38835户。 ...

Group 1 - The core viewpoint of the article highlights the performance of the Hubei state-owned enterprise reform sector, which increased by 1.6% compared to the previous trading day, with Guangji Pharmaceutical leading the gains [1] - On the same day, the Shanghai Composite Index closed at 4023.42, up by 1.38%, while the Shenzhen Component Index closed at 13828.63, up by 2.24% [1] - The main capital flow into the Hubei state-owned enterprise reform sector was a net inflow of 95.67 million yuan, while retail investors contributed a net inflow of 60.46 million yuan [1] Group 2 - The article provides a detailed overview of the capital flow, indicating that institutional funds had a net inflow, whereas speculative funds experienced a net outflow of 156 million yuan [1] - The performance of individual stocks within the Hubei state-owned enterprise reform sector is summarized in a table, which is not included in the text [1]

Market Overview - The Shanghai Composite Index closed at 4023.42 points, above the six-month moving average, with an increase of 1.38% [1] - The total trading volume of A-shares reached 30,483.30 billion yuan [1] Stocks Above Six-Month Moving Average - A total of 313 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - BeiYikang (证券代: 920199) with a deviation rate of 19.09% and a price increase of 29.98% [1] - *ST Huike (证券代: 300561) with a deviation rate of 18.68% and a price increase of 19.99% [1] - Weisi Medical (证券代: 688580) with a deviation rate of 18.24% and a price increase of 20.00% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Garden Holdings (证券代: 300430) with a deviation rate of 13.12% and a price increase of 19.98% [1] - Hongya CNC (证券代: 301033) with a deviation rate of 13.22% and a price increase of 20.00% [1] - Zhongke Sanhuan (证券代: 688314) with a deviation rate of 12.97% and a price increase of 19.99% [1]

Core Viewpoint - Hubei state-owned assets are actively acquiring stakes in listed companies to enhance industrial upgrading and regional economic development, with a focus on strategic emerging industries such as new energy and semiconductors [1][2][3] Group 1: Acquisition Activities - Jingjiang Industry, a subsidiary of Hubei state-owned assets, proposed a 2.437 billion yuan acquisition plan to acquire an 18.66% stake in ST Yishite, aiming for control through voting rights arrangements [1] - In 2023-2025, Hubei state-owned platforms are expected to control or plan to control approximately 15 A-share companies, including key players in the optoelectronics and new energy sectors [3] - The acquisition of companies like Kailong and Taiji reflects Hubei's strategy to build an industrial cluster covering various emerging sectors [2][3] Group 2: Strategic Framework - Hubei's "51020" modern industrial cluster strategy aims to establish five trillion-level pillar industries, ten 500 billion-level advantageous industries, and twenty 100 billion-level characteristic industrial clusters [1][2] - The provincial government has set ambitious goals for state-owned enterprises, including entering the ranks of the world's top 500 companies by 2027 [2] Group 3: Unique Acquisition Model - Hubei's acquisition model emphasizes maximizing capital efficiency, with strategies such as acquiring voting rights at a lower cost and quickly integrating acquired companies into existing projects [5][6] - The model includes a focus on global asset selection, integrating external assets into Hubei's industrial chain, and implementing risk prevention measures in acquisition agreements [5][6] Group 4: Impact on Local Economy - The acquisitions are expected to enhance the credit ratings of the acquired companies, reduce financing costs, and improve governance structures, thereby increasing operational efficiency and profitability [8] - Hubei state-owned assets aim to create a "technology + capital + industry" ecosystem, integrating local resources with industry trends to foster growth in strategic sectors [7][8]

Group 1 - The company held its 13th temporary board meeting on December 12, 2025, where several key resolutions were passed [2][3][6] - The board approved the acquisition of two plots of state-owned land totaling 13,080.40 square meters (approximately 19.62 acres) for a total amount of RMB 6,712,946.60 [3][11][12] - The company will sign a land use rights acquisition agreement with the Wuxue City Land Acquisition and Storage Center [11][12][20] Group 2 - The company applied for a comprehensive credit limit of RMB 125 million from Huaxia Bank, which will be used for purchasing raw materials and covering operational expenses [23][24][26] - The board approved the application for the credit limit with a unanimous vote of 9 in favor [25] - The credit limit will not adversely affect the company's daily operations [26] Group 3 - The company also applied for a comprehensive credit limit of RMB 30 million from the China Export-Import Bank, which will be used for trade finance [29][30] - The board approved this application with a unanimous vote of 9 in favor [32] - The cumulative credit limit applied to the China Export-Import Bank now totals RMB 130 million, with RMB 90 million remaining unused [34]

格隆汇12月12日丨广济药业(000952.SZ)公布，公司拟与武穴市征地和土地收储中心签署《国有土地使 用权收购协议书》，武穴市征地和土地收储中心拟对公司位于武穴市粮食路13号两宗总面积为13,080.40 平方米（合19.62亩）的国有土地使用权及房屋建筑物、构筑物等进行协商收储。本次土地收储收购总 额为人民币6,712,946.60元。 ...

证券代码：000952 证券简称：广济药业 公告编号：2025-063 湖北广济药业股份有限公司 关于向中国进出口银行湖北省分行 申请 3000 万元综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 湖北广济药业股份有限公司（以下简称"广济药业"或"公司"）于 2025 年 12 月 12 日召开第十一届董事会第十三次（临时）会议，审议通过了《关于公司向中国进出口 银行湖北省分行申请 3000 万元综合授信额度的议案》，具体情况如下： 一、申请综合授信情况 根据生产经营和业务发展需要，公司向中国进出口银行湖北省分行申请贸易金融额 度 3000 万元，授信期限 1 年，授信品种不限于保理 E 贷（可用于广济药业(孟州)有限 公司支付供应商货款）、国内订单融资、工商企业代付等业务，借款期限不超过 1 年， 年综合成本不超过 2.8%，担保方式为抵押（以武穴市大金镇张榜村宋煜村刘元村（武穴 国用（2012）第 072407036 号、武穴国用（2012）第 072407041 号）、武穴市大金镇张 榜村广济药业生物产业园－危险品库等 2 户（鄂（2 ...

一、签字注册会计师变更情况 利安达会计师事务所（特殊普通合伙）作为公司 2025 年度财务报表审计机 构和 2025 年度内部控制审计机构，原委派江正元先生作为签字项目合伙人、周 志军先生为签字注册会计师。鉴于原签字注册会计师江正元、周志军需参加其他 项目，利安达会计师事务所（特殊普通合伙）现委派张立先生、张静女士为变更 后的签字注册会计师，继续完成公司 2025 年度财务报表审计和内部控制审计相 关工作。本次变更后，公司 2025 年度审计项目的签字注册会计师为张立先生、 张静女士。 二、本次变更人员的基本信息、诚信记录和独立性情况 证券代码：000952 证券简称：广济药业 公告编号：2025-064 湖北广济药业股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 湖北广济药业股份有限公司（以下简称"公司"）分别于 2025 年 5 月 23 日 召开第十一届董事会第八次（临时）会议、第十一届监事会第七次（临时）会议， 2025 年 6 月 13 日召开 2025 年第二次临时股东会，审议通过《关于拟续聘会计 师事务 ...